SEC Contract Filing

Filing Date: 2017-10-20

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d466476dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS
PURCHASE AGREEMENT (the &#147;<B>Agreement</B>&#148;) is made as of the 17<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of October, 2017, by and among Syndax Pharmaceuticals, Inc., a Delaware corporation (the
&#147;<B>Company</B>&#148;), and the investors set forth on the signature pages hereto (the &#147;<B>Investors</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THE PARTIES
HEREBY AGREE AS FOLLOWS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;Purchase and Sale of Stock. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Sale and Issuance of Common Stock. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;On or prior to the
Closing (as defined below), the Company shall have authorized the sale and issuance to the Investors of an aggregate of 2,021,018 shares of the Company&#146;s common stock, $0.0001 par value (the &#147;<B>Common Stock</B>&#148;) at a purchase price
of $12.37 per share (the &#147;<B>Per Share Purchase Price</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions of
this Agreement, each Investor, severally and not jointly, agrees to purchase at the Closing and the Company agrees to sell and issue to such Investor at the Closing the number of shares of the Company&#146;s Common Stock set forth on such
Investor&#146;s signature page hereof at the Per Share Purchase Price (the &#147;<B>Stock</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Closing.</B> The purchase and sale of the Stock shall take place at the offices of Cooley LLP located at
3175 Hanover Street, Palo Alto, California 94304 at 10:00 A.M. Pacific Time, on October&nbsp;20, 2017, or at such other time and place as the Company and the Investors may mutually agree upon in writing (which time and place are designated as the
&#147;<B>Closing</B>&#148;). At the Closing, the Company shall cause (a)&nbsp;its transfer agent to deliver to each Investor, via electronic book-entry, the Stock that such Investor is purchasing against payment of the purchase price therefor by
wire transfer of immediately available funds to an account specified by the Company in writing to the Investors and (b)&nbsp;its outside legal counsel, Cooley LLP, to deliver to each Investor a legal opinion in a form to be agreed to between the
Company and the Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Representations and Warranties of the Company.</B> The Company hereby represents and
warrants to each Investor that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;The Company meets the requirements for use of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), and has filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a registration statement on
such Form (Registration File <FONT STYLE="white-space:nowrap">No.&nbsp;333-217172),</FONT> which became effective as of April&nbsp;20, 2017, for the registration under the Securities Act of the Stock. Such registration statement meets the
requirements set forth in Rule 415(a)(1)(x) under the Securities Act and complies with said Rule. The Company will file with the Commission pursuant to Rule 424(b) under the Securities Act, and the rules and regulations (the &#147;<B>Rules and
Regulations</B>&#148;) of the Commission promulgated thereunder, a supplement to the form of prospectus filed with the Commission on April&nbsp;6, 2017. Such registration statement, including the exhibits thereto, as amended at the date of this
Agreement, is hereinafter called the &#147;<B>Registration Statement</B>&#148;; such prospectus in the form filed with the Commission on April&nbsp;6, 2017, is hereinafter called the &#147;<B>Base Prospectus</B>&#148;; and the supplemented form of
prospectus, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the form in which it will be filed with the Commission pursuant to Rule 424(b) (including the Base Prospectus as so supplemented) is hereinafter called the &#147;<B>Prospectus
Supplement</B>.&#148; Any reference herein to the Registration Statement, the Base Prospectus or the Prospectus Supplem